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Abstract
Emerging evidence suggested a converging mechanism in neurodegenerative brain diseases (NBD) involving early neuronal 
network dysfunctions and alterations in the homeostasis of neuronal firing as culprits of neurodegeneration. In this study, 
we used paired-end short-read and direct long-read whole genome sequencing to investigate an unresolved autosomal 
dominant dementia family significantly linked to 7q36. We identified and validated a chromosomal inversion of ca. 4 Mb, 
segregating on the disease haplotype and disrupting the coding sequence of dipeptidyl-peptidase 6 gene (DPP6). DPP6 
resequencing identified significantly more rare variants—nonsense, frameshift, and missense—in early-onset Alzheimer’s 
disease (EOAD, p value = 0.03, OR = 2.21 95% CI 1.05–4.82) and frontotemporal dementia (FTD, p = 0.006, OR = 2.59, 95% 
CI 1.28–5.49) patient cohorts. DPP6 is a type II transmembrane protein with a highly structured extracellular domain and 
is mainly expressed in brain, where it binds to the potassium channel  Kv4.2 enhancing its expression, regulating its gating 
properties and controlling the dendritic excitability of hippocampal neurons. Using in vitro modeling, we showed that the 
missense variants found in patients destabilize DPP6 and reduce its membrane expression (p < 0.001 and p < 0.0001) leading 
to a loss of protein. Reduced DPP6 and/or  Kv4.2 expression was also detected in brain tissue of missense variant carriers. 
Loss of DPP6 is known to cause neuronal hyperexcitability and behavioral alterations in Dpp6-KO mice. Taken together, 
the results of our genomic, genetic, expression and modeling analyses, provided direct evidence supporting the involvement 
of DPP6 loss in dementia. We propose that loss of function variants have a higher penetrance and disease impact, whereas 
the missense variants have a variable risk contribution to disease that can vary from high to low penetrance. Our findings of 
DPP6, as novel gene in dementia, strengthen the involvement of neuronal hyperexcitability and alteration in the homeostasis 
of neuronal firing as a disease mechanism to further investigate.
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Background
Considerable progress has been made towards understand-
ing the genetic origin, the neuropathology and the epide-
miology of neurodegenerative brain diseases (NBD) such 
as Alzheimer’s disease (AD) and frontotemporal dementia 
(FTD). Linkage analyses and large-scale genomics studies, 
have shown that a wide genetic heterogeneity is responsible 
for the neuronal pathologies and dysfunctions in NBD [6, 
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34, 61], with yet additional causes to identify and mecha-
nisms to discover. Many disorders of the central nervous 
system (CNS) show a broad array of clinical features, e.g., 
impaired behavior, language, etc., but some of them, such 
as alterations in memory, are shared across disorders [7, 28, 
55]. Several emerging concepts suggest a converging mecha-
nism in NBD involving early neuronal network dysfunctions 
[58, 84] and alterations in the homeostasis of neuronal firing 
[24] as culprits of neurodegeneration [24, 58, 84]. This is 
supported by studies in mouse models of AD, in which was 
shown that higher firing rates can promote amyloid-β (Aβ) 
production [84] and that the neuronal hyperactivity precedes 
the deposition of plaques [5]. Studies using functional mag-
netic resonance (fMRI) demonstrated hippocampal activa-
tion in both patients with amnestic mild cognitive impair-
ment (aMCI) [16] and preclinical carriers of inherited causal 
mutations in familial AD [64] as well as FTD patients [83]. 
These are only some examples of an emerging field, which 
spurs the investigation of these new mechanisms to better 
understand neurodegenerative dementia and to design more 
effective treatments [3, 58]. Despite the diverse mechanistic 
insights [24, 58, 84], additional data are necessary to better 
understand the pathophysiology of the early dysfunctions 
of circuits and neurons. Our discoveries, started with an in 
depth examination of an unexplained linked locus on chro-
mosome 7q36 (size 5.44 Mb and LOD score = 3.39 at θ = 0) 
[65] and resulted in the finding of dipeptidyl-peptidase 6 
(DPP6) as novel gene in NBD. DPP6 is a single pass type II 
transmembrane protein expressed in brain, where it forms 
a multimeric complex with the potassium channel  Kv4.2, 
regulating the voltage-dependent gating properties and the 
surface expression of  Kv4.2 in the brain [60] playing a cru-
cial role in neuronal excitability [73]. With this study we 
provided direct genetic evidence to support the involvement 
of neuronal hyperexcitability and alteration in the homeo-
stasis of neuronal firing as disease mechanisms in dementia.
Materials and methods
Family 1270
The proband of family 1270, aged 47 years, was ascertained 
in the frame of the Dutch population-based epidemiologi-
cal study of early-onset AD in 1980–1987 [30]. The 1270 
family, with a history of autosomal dominant inheritance 
[29, 76], was sampled for genetic studies in the 80–90’s. 
Diagnoses of AD were made according to National Insti-
tute of Neurological and Communicative Diseases and 
Stroke–Alzheimer’s Disease and Related Disorders Asso-
ciation (NINCDS-ADRDA) criteria published in 1984 [49], 
and of mild cognitive impairment (MCI) according to Honig 
and Mayeux [31]. Linkage analyses for loci on chromosomes 
14, 19, and 21 [76], and mutation screening of the AD genes, 
APP (21.q21.1), PSEN1 (14q24.3) and PSEN2 (1q42.1), 
were negative [11, 75].
Follow-up clinical studies of family 1270, including 
neurological examination of incident patients, interviews 
of first-degree relatives and review of medical records and 
CT scans, identified four additional patients [65]. The onset 
age in the updated family was highly variable with a mean 
age at onset of 66.8 ± 7.4 years and range of 47–77 years. 
In the proband, and most other patients, the disease initially 
presented with memory impairment, except for one patient, 
in whom a change of personality was the initial complaint, 
which later in the disease course was followed by memory 
loss. In all patients the disease progressed into other areas 
of cognition, such as praxis and speech [65]. Neuroimaging 
was available for two patients, III-48 at age 74 years and III-
21 at age 82 years and showed cortical atrophy in both [65]. 
For the only living patient, III-21, who received the diag-
nosis of possible AD, a CT scan (at age 82 years) showed 
that cortical and subcortical atrophy was most notable in the 
temporal and frontal regions (supplementary material) [65]. 
A cohort of 82 Dutch EOAD patients [76], mean age at onset 
[AAO] ± standard deviation (SD) of 57.0 ± 5.6 years (82.3% 
women) was included for candidate gene resequencing.
Belgian patient and control cohorts
The Belgian AD cohort consisted of 558 patients (mean 
onset age 61.6 ± 6.8 years, range 33–70 years), of whom 
221 Belgian AD patients were referred to our molecular 
diagnostic unit for PSEN1, PSEN2, and/or APP mutation 
screening. Post-mortem brain analysis was performed in 
17 patients confirming AD pathology. The majority of the 
patients were recruited at the memory clinic of the hospitals 
Middelheim and Hoge Beuken of the Hospital Network Ant-
werp (ZNA), Belgium (P.P.D.D. and S.E.) [19, 20]. Another 
subset was collected at the Department of Neurology and 
the Memory Clinic of the University Hospitals of Leuven 
(UHL), Belgium (R.V.) as well as through the neurology 
centers of the clinical partners of the Belgian Neurology 
(BELNEU) consortium. Diagnosis of possible, probable 
or definite AD was obtained by consensus of at least two 
neurologists based on the NINCDS-ADRDA diagnostic cri-
teria [49] and the National Institute on Aging-Alzheimer’s 
Association (NIA-AA) diagnostic criteria [32, 50]. Each 
AD patient underwent a neuropsychological examination, 
including mini-mental state examination (MMSE) [23] and 
structural neuroimaging, while functional neuroimaging and 
cerebrospinal fluid analysis was done in a subset of patients 
[4]. The Belgian FTD cohort consisted of 614 patients 
(mean AAO 66.1 ± 9.9 years; age range 20–89 years), which 
included 35 patients with a concomitant amyotrophic lat-
eral sclerosis (FTD-ALS), recruited in the framework of 
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the BELNEU consortium [25, 78]. Clinical FTD diagnosis 
was made according to established clinical criteria [54, 66]. 
Post-mortem pathological analysis confirmed diagnosis in 
29 FTD and 3 FTD-ALS patients. In the screened cohort, a 
total of 100 patients carried a mutation in a known causal 
dementia gene: 51 patients (8.3%) carried a C9orf72 patho-
genic repeat expansion, 31 patients (5%) had a pathologi-
cal GRN mutation, five patients (0.8%) carried a mutation 
in TBK1, four patients (0.6%) had a mutation in MAPT, 
six patients (1%) had a VCP mutation, one patient had a 
CHMP2B mutation (0.2%), a TARDBP mutation (0.2%) 
or a PSEN1 mutation (0.2%). The Belgian control cohort 
consisted of 755 unrelated and non-demented individuals 
[mean age at inclusion (AAI), 71.6 ± 9.7 years; age range 
34–100 years]. In the selection of control persons, subjective 
memory complaints and neurological or psychiatric anteced-
ents, as well as a familial history of neurodegeneration, were 
ruled out by means of an interview. Cognitive screening was 
initially performed using the mini-mental state examination 
(MMSE, cutoff > 25) [23] but later the Montreal Cognitive 
Assessment (MoCA, cutoff > 25) [53] was also used. The 
majority of the control persons were community-dwelling 
volunteers. Additionally spouses of patients were included 
after examination at the Memory Clinic of the ZNA Mid-
delheim and Hoge Beuken hospitals, Antwerp, Belgium 
and the Memory Clinic of the University Hospitals Leuven, 
Gasthuisberg, Leuven, Belgium.
Ethical assurances
Ascertainment of the family 1270 relatives and the Dutch 
patients was performed in the Netherlands using a study 
protocol approved by the Medical Ethical Committee of the 
Erasmus Medical Center Rotterdam. All Belgian participants 
and/or their legal guardian signed a written informed con-
sent form for their participation in the clinical and genetic 
studies. The clinical and genetic study protocols and the 
informed consent forms were approved by the Ethics Com-
mittee of the University Hospital Antwerp and the Univer-
sity of Antwerp, and the respective hospitals of the members 
of the BELNEU consortium, Belgium.
Whole genome sequencing (WGS)
Short-read paired-ends WGS was performed at Complete 
Genomics Inc. (Mountain View, CA USA) [18]. Raw 
sequencing reads were aligned to the reference genome 
(National Center for Biotechnology Information (NCBI) 
build 36 (hg18). Sequence alignment and variant calling 
were performed by Complete Genomics Inc. while data 
annotation and analysis were performed with the Genom-
eComb package [68]. Good quality variants were selected 
as previously described [68]. Additionally, novel or rare 
(minor allele frequency (MAF) < 1% in the 1000 Genome 
Project [2] and/or in our in-house database of WGS data 
of unrelated individuals (n = 82)), heterozygous variants 
shared among the four WGS patients were investigated. 
Sequenom MassARRAY ® (Agena Bioscience, CA, USA) 
and Sanger sequencing (BigDye Terminator Cycle Sequenc-
ing kit v3.1; analysis on an ABI 3730 DNA Analyzer, both 
Thermo Fisher Scientific, MA, USA) were used for vari-
ants validation. Structural variations (SV) were called by 
Complete Genomics and/or using a SV detection tool inte-
grated in GenomeComb [68] version 0.90.0 (available at 
http://genom ecomb .sourc eforg e.net). This tool scans the 
genome sequencing data for groups of read pairs that map 
at a distance that is markedly different from the expected 
insert size. Under normal conditions, the distance between 
the two sequence reads of a mate pair is expected to be 
approximately 350 bp corresponding to the size of selected 
fragments during WGS library construction. For the detec-
tion of inversions, groups of discordant mate pairs must be 
present for which the reads map at a different distance than 
expected and in opposite orientation. The linkage region 
between markers D7S636 and D7S559 [65] was analyzed 
for both single nucleotide variants (SNVs) as well as SV. 
Additionally, the public genome data repository of Complete 
Genomics Inc. containing freely accessible WGS data of 
69 individuals, 52 unrelated individuals (software version 
1.10.0; http://www.compl etege nomic s.com/publi c-data/) 
[18], as well as WGS data from 427 individuals (157 unre-
lated) sequenced by Complete Genomics Inc. (software ver-
sion 2.2.0) and distributed by the 1000 genome project [2] 
were used for comparative purposes.
Long-read direct WGS was performed in-house on 
the PromethION sequencing platform (Oxford Nanopore 
Technologies (ONT), UK). Prior to library preparation, 
the DNA was sheared to 35  kb using the Megaruptor 
(Diagenode, BE) and size selected to a minimal length of 
6 kb on the BluePippin (Sage Science, MA, USA) using a 
High-pass protocol and the S1 external marker on a 0.75% 
agarose gel (Sage Science, USA). The recommended SQK-
LSK109 protocol for library preparation for PromethION 
(ONT) sequencing was followed with slight increases in all 
enzymatic incubation times and during elution. In short, 
DNA template damage and ends were repaired in a com-
bined step using NEBNext FFPE DNA Repair Mix and 
NEBNext Ultra II ER/dAT Module (New England Biolabs, 
USA) followed by AMPureXP (Beckman Coulter, CA, 
USA) bead purification and ligation of platform-specific 
adapter sequences. The final library (100 fmol) was loaded 
on a PromethION flow cell with 8021 active pores at the 
start, following the default protocol for PromethION DNA 
sequencing. Base calling of the raw reads was performed 
using the ONT basecaller Guppy (v1.4.0) on the Prome-
thION compute device. Run metrics were calculated and 
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visualized using NanoPack [12]. Reads were aligned to 
hg19 using ngmlr (v0.2.6) [70] using default parameters. 
Inversions were detected using npInv inversion caller [71]. 
The coverage was assessed using mosdepth [59]. Long-
read WGS of ten unrelated individuals (eight dementia 
patients and two controls) generated in-house following 
the same pipeline was used for comparison purposes.
DNA local alignment analysis of the NCBI hg19 reference 
sequence of chromosome 7: 149,169,800–154,794,690 bp 
was performed using YASS [57].
Directional genomic hybridization (dGH™) analysis
Directional genomic hybridization (dGH™) [67] analysis of 
chromosome 7 was performed by KromaTiD, Inc. (Fort Col-
lins, Colorado, http://www.kroma tid.com/) using the dGH™ 
C7 Paint assay (D3P-HC710) on Epstein–Barr virus (EBV) 
immortalized lymphoblast cell lines fixed in metaphase after 
one replication cycle in the presence of Brd-U and Brd-C. 
Single-stranded sister chromatids were hybridized with 
high density directional probes. Inverted fragments inher-
ently possess an opposite 5′ → 3′ orientation, resulting in 
a switch of fluorescent hybridization signal from one sister 
chromatid to the other.
Whole gene resequencing
Resequencing of the complete coding region (CDS) of DPP6 
(NM_130797.3), including two alternatively spliced exon 
1 (NM_001936.4 and NM_001039350.2) and intron/exon 
boundaries, was achieved using a custom-designed gene 
panel (Agilent Technologies, CA, USA) [26] combined with 
massive parallel sequencing (MPS) on a  MiSeq® sequencer 
 (Illumina®, San Diego, CA, USA). Read processing, align-
ment and variant calling were performed in-house with a 
standardized pipeline integrated in GenomeComb [68]. The 
pipeline used fastq-mcf [1] for adapter clipping. Reads were 
then aligned using bwa [41]. Realignment in the neighbor-
hood of indels was performed with GATK [15]. All positions 
with a coverage ≥ 5 were variant called using GATK [15]. 
At this initial stage positions with a coverage < 5 or a score 
< 30 were considered unsequenced. The resulting variant 
sets of different individuals were combined and annotated 
using GenomeComb [68]. Downstream data analysis was 
further performed with the same software [68]. Exon 1 of 
DPP6 isoform 1 (NM_130797.3), due to high GC content 
and genomic complexity, was sequenced upon PCR ampli-
fication with specific primers. PCR products were pro-
cessed by direct Sanger sequencing as described earlier in 
the text. Sanger sequencing was also used for validation of 
the identified variants after gene panel sequencing assay, 
using exon-specific primer pairs (sequences available upon 
request).
Variants modeling
Prediction of deleteriousness of the nucleotide changes for 
the DPP6 variants was performed using Combined Annota-
tion Dependent Depletion (CADD) version 1.3. The rescaled 
(PHRED) score is reported, which correlates with allelic 
diversity and variants pathogenicity [37]. The investigation 
of the effect of the amino acid changes on protein stabil-
ity (difference in free Gibbs energy) and the interaction 
with functional residues (i.e., glycosylation sites) were per-
formed with FoldX (http://foldx .crg.es/) and YASARA [39, 
77]. This analysis was limited to the extracellular domain, 
because only the crystallographic structure of this protein 
domain is available. DPP6 protein data bank accession num-
ber: 1XFD.
DPP6 transmembrane protein stability assay
Gateway and In-Fusion cloning (both Invitrogen, Thermo 
Fisher Scientific, Waltham MA, USA) were used to generate 
the wild-type DPP6 pCR3 expression construct C-terminally 
fused with the HiBit sequence as well as a control construct 
including a PEST sequence in between DPP6 and the HiBit 
sequence (constructs available upon request). Mutations of 
interest were introduced in the wild-type DPP6 construct 
by site directed in vitro mutagenesis using KAPA HiFi Hot-
Start DNA polymerase (Kapa Biosystems, MA, USA). A 
construct containing the sequence of the secreted Gaussia 
luciferase (GLuc) was used for normalization purposes. 
HEK293T cells were co-transfected with DPP6 and GLuc 
constructs (4:1 ratio) using XtremeGene9 (Sigma-Aldrich, 
MO, USA). Non-transfected cells were included as a control. 
Gaussia luciferase and Nano-Glo® HiBit luciferase signals 
were detected 48 h after transfection by the use of BioLux 
Gaussia Luciferase Assay Kit (New England Biolabs, MA, 
USA) and a Nano-Glo® HiBit Extracellular detection Sys-
tem (Promega Corporation, WI, USA), respectively. Both 
the GLuc and the Nano-Glo® HiBiT luminescence signal 
(LUC) were measured following the manufacturer guide-
lines using a  GloMax®96 microplate luminometer (Promega 
Corporation, WI, USA). The injector option was used for 
detection of GLuc activity. All construct concentrations and 
LUC signals were initially optimized to be within the linear 
range of detection. For data analysis, relative LUC activity 
was calculated as Nano-Glo® HiBiT luciferase signals nor-
malized to GLuc signals. Six independent experiments were 
performed and the resulting data per construct were pooled 
together for statistical analysis.
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DPP6 mRNA and protein analyses
Semi-quantitative real-time PCR (qRT-PCR) was used to 
quantify brain expression levels of total DPP6. Expres-
sion levels were measured in the frontal cortex (BA10) of 
patient-specific variant carriers (n = 3) and control individu-
als (n = 4). Total RNA was isolated from fresh frozen brain 
tissue using the RiboPure™ kit followed by DNase treat-
ment with TURBO DNase (both Ambion, Thermo Fisher 
Scientific, MA, USA). First-strand cDNA was synthetized 
utilizing the  SuperScript® III First-Strand Synthesis System 
(Thermo Fisher Scientific, MA, USA) with random hexamer 
primers. qRT-PCR reactions were performed using the Fast 
 SYBR® Green chemistry (Thermo Fisher Scientific, MA, 
USA) and run on the ViiA™ 7 Real-Time PCR System 
(Thermo Fisher Scientific, MA, USA). Quantification of 
mRNA levels was achieved with glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), tyrosine 3-monooxygenase/
tryptophan 5-monooxygenase activation protein, zeta poly-
peptide (YWHAZ), hypoxanthine phosphoribosyltransferase 
1 (HPRT1), TATA box binding protein (TBP) as internal 
control genes, all with moderate to high expression in neu-
rons (https ://www.prote inatl as.org/). Normalization to the 
reference genes was achieved through geometric averaging 
of the expression levels, as described by Vandesompele and 
colleagues [80]. Each sample was measured in triplicate and 
three independent experiments were performed.
Protein lysates from fresh frozen human brain tissue were 
made in modified radioimmunoprecipitation (RIPA) buffer 
(150 mM NaCl, 0.5% sodium deoxycholate, 1% NP-40, 
50 mM Tris–HCl; pH 8.0) supplemented with 1% sodium 
dodecyl sulfate (SDS), as described previously [38]. Pro-
tein preparations from mutation carriers and control indi-
viduals were separated on 4–12%  NuPAGE® Bis–Tris gel 
(Thermo Fisher Scientific, MA, USA) and electroblotted 
onto a polyvinylidene difluoride membrane (PVDF, Hybond 
P; Amersham Biosciences, GE Healthcare Life Sciences, 
Buckinghamshire, UK). Membranes were probed with pri-
mary antibodies to detect DPP6 (1:10,000 AVIVA System 
Biology, ARP44867_P050, San Diego, CA, USA),  Kv4.2 
(1:1000 Abcam, (EP982Y) ab46797, Cambridge, UK) and 
GAPDH (1:20,000 GeneTex, GTX100118, Irvine, CA, 
USA). Immunodetection was performed with specific sec-
ondary antibodies conjugated with horseradish peroxidase 
(HRP) and the ECL-plus chemiluminescent detection system 
(GE Healthcare Life Sciences). Western blot results were 
visualized and quantified using the ImageQuant™ LAS4000 
digital imaging system and the ImageQuant™ TL software 
(GE Healthcare Life Sciences, Buckinghamshire, UK). Inde-
pendent protein preparations and western blot experiments 
were performed three times.
Statistical analyses
For the rare variants analysis, power calculation was per-
formed within the SKAT framework in R (version 3.1.2). 
A logistic test for dichotomous traits with a SKAT-O model 
was used (target sequence: 3545 bp, causal variant percent-
age = 40%, protective variant percentage = 10%, Maximal 
OR = 5). Under these conditions both patient-control cohorts 
(> 1300 individuals) reached the power requirement level 
of 80% with a 0.05 significance level, since the total sample 
Fig. 1  Segregation of DPP6 in family 1270. Segregation analysis 
of three rare variants identified in WGS data in intron 1 of DPP6 
(hg18 variant 1 g.153577081 A>G, variant 2  g.153737600 C>T; 
rs567013292 and variant 3 g.153744958 G>T) delimited by the STR 
markers D7S798 and D7S2546. Black bars represent the disease hap-
lotype of patients. Numbers within each diamond are unaffected indi-
viduals, non-carriers of the disease haplotype included in the geno-
typing. Arabic numbers above the symbols denote individuals, Arabic 
numbers below the symbols denote age at onset for patients or either 
age at last examination or age at death for unaffected individuals. The 
arrow identifies the proband in the family. WGS data were gener-
ated for patients III-12, III-38, III-41, and III-48 from three different 
sib ships of the pedigree. Direct long-read WGS on Oxford Nanop-
ore PromethION sequencer was performed for III-48. Directional 
genomic hybridization was performed in cell lines derived from 
patient III-48 (Fig. 3) and from the non-carriers III-23 and III-39
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cohort required for this level is at least 925 individuals. 
Gene-based burden analysis of rare variants (minor allele 
frequency (MAF) < 1%) was performed with SKAT-O in 
R, version 3.1.2, using the SKAT package. Adjustment was 
applied because the sample size was < 2000. A two-sided 
p value < 0.05 was considered significant. Odds ratio (OR) 
and 95% confidence interval (CI) were calculated using an 
allelic Fisher’s exact test. To investigate the effect of DPP6 
rare variants on AAO, disease duration (DD) and family 
history (FH), we tested the patients with available records 
of the specific phenotypical traits. Patients carrying a DPP6 
variant were compared to the non-carrier patients’ cohorts. 
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Patients with a pathogenic mutation in known causal genes 
were excluded. A two-tailed non-parametric Mann–Whit-
ney U test was applied to test for an effect on AAO and DD 
in GraphPad Prism 6 (La Jolla, CA, USA). A χ2 test was 
applied to test for enrichment in familial load in carriers of 
DPP6 rare variants compared to non-carrier patients. For 
the mRNA expression studies, three qRT-PCR experiments 
were independently normalized as previously described [80] 
and the results were pooled. The non-parametric two-tailed 
Mann–Whitney U test was used to compare the expression 
of total DPP6 levels between patients, carriers of DPP6 
variants and control individuals in GraphPad Prism 6 (La 
Jolla, CA, USA). A two-tailed p value < 0.05 was considered 
significant. Western blot results were quantified using the 
ImageQuant™ TL software (GE Healthcare Life Sciences, 
Buckinghamshire, UK). Relative protein expression levels 
between mutation carriers and control individuals were ana-
lyzed using a two-tailed Student’s t test. A p value < 0.05 was 
considered significant. For the protein stability assay, the 
normalized LUC values of six experiments were pooled per 
variant and compared to the wild-type levels using a non-
parametric Kruskal–Wallis test in combination with a post 
hoc Dunn’s test in GraphPad Prism 6 (La Jolla, CA, USA).
Results
Family 1270
Earlier, the overall clinical picture of dementia in the muti-
generational family 1270 was reported to be compatible with 
AD (Fig. 1, Fig. S1) [65, 76]. However, at the time of diag-
nosis of the index patient and of the affected relatives, cere-
brospinal fluid (CSF) biomarkers and amyloid brain imaging 
were not available. Also, there was no autopsied brain avail-
able to obtain a definite diagnosis of dementia subtype based 
on neuropathology. Previous genetic analyses in the linked 
locus 7q36 in family 1270 [65] identified seven variants 
in five different genes: ATP-binding cassette subfamily F, 
member 2 (ABCF2); N-acetylgalactosaminyltransferase 11 
(GALNT11); DPP6; PAX transcription activation domain 
interacting protein (PAXIP1) and Engrailed 2 (EN2), which 
were segregating on the disease haplotype in family 1270 
[65]. Most of these variants were synonymous and only the 
PAXIP1 p.A660 variant was absent from control individuals 
[65]. Current public genetic data (e.g., ExAc) [40], showed 
different nucleotide changes in PAXIP1, leading to the same 
silent variant (p.A660), making it unlikely that the PAXIP1 
variant has a deleterious effect. Further, we found no evi-
dence for aberrant splicing of PAXIP1 in lymphoblast cells 
of patients [65].
WGS analysis of single nucleotide variants 
in the 7q36 locus
In family 1270 (Fig. S1), we performed paired-end WGS 
on high molecular weight genomic DNA of four patients in 
three different sibships of generation III, i.e., patients III-
12, III-38, III-41, and III-48 (Fig. 1). On average 95.5% of 
the genome sequence had reliable diploid calls in all four 
patients. The genetic variants were annotated and good qual-
ity [68], rare or heterozygous non-coding variants (< 1% in 
1000 Genome Project) [2], that were shared between the 
four patients, were further investigated. In the linked locus, 
between STR markers D7S636 and D7S559 [65], variant 
selection retained 79 non-coding variants. Validation and 
segregation analysis in family 1270 retained 38 non-coding 
variants that co-segregated in family 1270 on the disease 
haplotype. Genotyping of the variants in control individu-
als, showed that four of the variants were unique to family 
1270 (Fig. 1). Variant 1 (chr7:g.153577081 A>G), variant 
2 (chr7:g.153737600 C>T; rs567013292), and variant 3 
(chr7:g.153744958 G>T) are all located in intron 1 of DPP6 
(Figs. 1, 2). Variant 4 (chr7:g.155325040 G>C) mapped in 
an intergenic region, 27.3 kb distal of the closest gene SHH 
(Fig. 2), which is located within the linked locus, 908 kb 
downstream of DPP6. None of the four variants had a high 
disruptive potential based on the ENCODE [69] annotation.
To exclude that coding variants outside the linked locus 
were causing the disease, we extracted the exome from the 
WGS data and analyzed the presence of rare and/or novel 
coding non-synonymous variants. Heterozygous variants, 
shared by the four patients, were selected (UTRs, synony-
mous and non-synonymous), and filtered based on quality 
[68] and frequency similar as for the non-coding variants. 
Only the rare/novel (< 1% in 1000 Genome Project) [2] vari-
ants in known protein coding genes, that predicted to impact 
Fig. 2  DNA local alignment and schematic representation of 7q36 
inversion disrupting DPP6. a DNA local alignment analysis of the 
NCBI hg19 reference sequence of chromosome 7: 149,169,800–
154,794,690  bp shows inverted low copy repeats (LCRs) indicated 
by blue triangles. The horizontal green bar represents the candi-
date region of 5.44  Mb (reference build hg19) linked to 7q36 in 
family 1270, between the short tandem repeats (STRs) markers 
D7S636 and D7S559 [65]. The dotted vertical lines mark the loca-
tions of the proximal and distal inversion breakpoints, with the distal 
breakpoint in DPP6 (black bar) and the proximal breakpoint in the 
intergenic region between the genes ATP6V0E2 and ACTR3C (blue 
bars). Red rectangles magnify the location of the proximal and dis-
tal breakpoints. The distal breakpoint is located within the intron 1 
of DPP6. Three isoforms are reported in the figure with independ-
ent transcription starting sites and regulatory elements (top right red 
rectangle). b Visualization of the 180° flip of the genomic sequence 
by the inversion, separating the regulatory region and exon 1 from the 
coding sequence of DPP6. c Magnification of the region around the 
distal inversion breakpoint in intron 1 of DPP6 between D7S798 and 
D7S2546 (red bar) and the location of the three co-segregating rare 
variants identified by WGS studies. The fourth segregating variant 
(variant 4) is reported in a downstream of the SHH gene (grey)
◂
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the protein sequence (non-synonymous), were validated. 
This selection generated nine non-synonymous variants 
(Table S1), but none co-segregated with disease in family 
1270.
An inversion of 4 Mb disrupting the DPP6 sequence 
was detected in the linked 7q36 locus
Investigation of the variants within the linked region evi-
denced the presence of inverted low copy repeats (LCRs) 
in the 7q36 locus. In silico simulation of amplification of 
primers, designed to validate these variants, showed PCR 
products that aligned in opposite orientations at two loci on 
chromosome 7, separated from each other by about 4 Mb. 
Local alignment of the DNA regions between 149,169,800 
and 154,794,690 bp on chromosome 7 (hg19), confirmed 
the presence of inverted paralogous low copy repeats (IP-
LCRs) with > 98% sequence homology and located ca. 4 Mb 
apart (Fig. 2). Bioinformatics analysis of the WGS data of 
the four patients identified a paracentric (sub-telomeric) 
inversion in the q-arm of chromosome 7 of about 4 Mb 
(inv(7)) (Fig. S2) with the inversion breakpoints located 
within the IP-LCRs regions (Fig. 2). The distal breakpoint 
is located within the linked locus at 7q36.2, in intron 1 of 
Fig. 3  Inversion validation by 
directional genomic hybridiza-
tion. a Schematic presentation 
of the chromosome 7 directional 
genomic hybridization (dGH™) 
assay. b In vitro visualization of 
the inversion in patient III-48 
using a directional genomic 
hybridization (dGH™) assay. 
The inverted fragment is 
observed as a signal switch 
between the sister chromatids 
(arrowhead in the magnified 
image c). No signal is present 
in the normal chromosome 7 
(magnified image d)
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dipeptidyl-peptidase 6 (DPP6), and it is predicted to dis-
rupt the coding sequence of the gene (Fig. 2). The proximal 
inversion breakpoint is located outside the linked locus, 
in an intergenic region between proximally ATP6V0E2 at 
122 kb and distally ACTR3C at 243 kb (Fig. 2). These results 
were confirmed by direct long-read WGS on PromethION 
performed for patient III-48. The sequence run generated 
21.2 Gbase of data resulting in a median coverage of 6×. 
The npInv inversion caller [71] independently identified an 
inversion at chr7:149,704,610–153,786,893 confirming the 
previous findings. The inversion at 7q36.2, with one break-
point in intron 1 of DPP6, was not detected in publicly avail-
able WGS data of 209 unrelated individuals, all sequenced 
with the same short-read sequencing technology. Also, the 
inversion was not present in long-read WGS of ten unrelated 
dementia patients and control persons, generated by us using 
the Oxford Nanopore PromethION sequencer.
In vitro visualization of the 7q36 inversion
We successfully visualized the inv(7) in lymphoblast cells 
of patient III-48 (Fig. 3) using directional genomic hybridi-
zation (dGH™) [66]. The inverted chromosomal fragments 
inherently possess an opposite 5′ → 3′ orientation, resulting 
in a jump of fluorescent hybridization signal from one sister 
chromatid to the other. We also confirmed that this structural 
Table 1  Rare variants in DPP6 in Belgian patient cohorts
The table lists phenotypic and genetic information of rare variants (MAF ≤ 1%) found only in patients. DPP6 sequencing in 82 patients of the 
original Dutch population-based EOAD cohort, to which the proband (III-47) of family1270 belonged, identified 1 patient carrying the vari-
ant p.R322H, not included in statistical analysis. The specific topological domains in which the mutations are detected are indicated: intracel-
lular domain (IC) of isoform 1 (Is 1, NM_130797.3) and isoform 3 (Is 3 NM_001039350.2); transmembrane (TM) and extracellular domain 
(EC) common to all DPP6 isoforms. One variant (p.A5D) was found in the alternative coding exon 1 of isoform 3 in a FTD patient (DR1149). 
Individuals marked in bold have brain autopsy available (Supplementary material Fig. S3–S4), with a definite diagnosis of FTLD-TDP type D 
(DR40), definite AD (DR414) and FTLD-ALS type B (DR1152). Individuals marked with an asterisk (*) carry a known pathogenic mutation in 
VCP (p.R159H, DR40) and in C9orf72 (repeat  G4C2 expansion, DR1198). Abbreviations: AAO age at onset, AAI age at inclusion, AD Alzheimer 
disease, ALS amyotrophic lateral sclerosis, FTD frontotemporal dementia, PPA primary progressive aphasia. Genomic DNA (g.DNA) is the 
chromosomal position relative to hg19 build of the reference genome
Patient Clinical diagnosis AAO (years) AAI (years) g.DNA c.DNA Protein Protein domain
DR1149 FTD 77 79 g.153584782 c.14C>A p.A5D IC Is 3
DR1143 AD 58 67 g.153749963 c.58G>A p.A20T IC Is 1
g.153750014 c.109G>A p.G37S IC Is 1
DR1350 FTD-PPA 74 g.153750014 c.109G>A p.G37S IC Is 1
DR40* FTD 44 50 g.153750044 c.140G>T p.R47L IC Is 1
DR623 FTD – 71 g.153750044 c.140G>T p.R47L IC Is 1
DR1144 AD 59 61 g.153750065 c.160C>G p.R54G IC Is 1
DR807 FTD 65 g.153750065 c.160C>G p.R54G IC Is 1
DR1351 AD 56 g.153750065 c.160C>G p.R54G IC Is 1
DR1352 AD 55 g.153750065 c.160C>G p.R54G IC Is 1
DR1147 FTD 65 65 g.153750086_153750091 c.182_187dup p.G61_G62dup IC Is 1
DR1145 FTD-ALS 76 g.153750140_153750141 c.235_236dupG p.E79Gfs*9 IC Is 1
DR1153 FTD 67 g.154143386 c.331G>A p.V111I TM
DR1151 FTD 63 g.154172048 c.383A>G p.K128R EC
DR1198* FTD 52 g.154263996 c.622G>C p.E208Q EC
DR1150 PPA 80 81 g.154461074 c.685C>A p.P229T EC
DR1154 FTD – 67 g.154461077 c.688C>T p.Q230* EC
DR1155 AD 68 68 g.154519535 c.821G>A p.R274H EC
DR1156 AD 53 g.154561208 c.965G>A p.R322H EC
DR1289 AD 59 g.154564586 c.1070A>G p.H357R EC
DR414 PPA 57 59 g.154596653 c.1526C>G p.P509R EC
DR1152 FTD-ALS 75 75 g.154645528 c.1705G>A p.D569N EC
DR1353 FTD 65 g.154645534 c.1711A>C p.K571Q EC
DR1354 AD 63 g.154645534 c.1711A>C p.K571Q EC
DR114 FTD 67 68 g.154667696 c.1964C>T p.A655V EC
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variation was absent in two healthy relatives who did not 
carry the disease haplotype (III-23 and III-39).
Rare variants in DPP6 are associated 
with neurodegenerative dementia
To better understand the genetic contribution of DPP6 to 
NBD, we performed massive parallel gene resequencing of 
Fig. 4  RNA and protein expression levels of DPP6 missense vari-
ants. a Scatter plot of the DPP6 mRNA expression levels in patients 
(n = 3) compared to control individuals (n = 4). Each circle (patients) 
or square (control individuals) represents a single measurement; the 
graph reports the mean ± standard error of the mean (s.e.m.). **p 
value = 0.0096. b DPP6 mRNA expression level results of three 
experiments for each of the variants (grey bars) compared to averaged 
data of four controls (black bar). c Western blot of DPP6 carriers and 
control individuals and e western blot of  Kv4.2 in DPP6 variant carri-
ers and control individuals. d, f Quantification of the expression lev-
els of DPP6 (d) and Kv4.2 (f), obtained from pooling two independ-
ent protein preparations within the same western blot experiment. 
Quantifications are shown for each of the missense variants (grey 
bars) compared to control individuals (n = 3, black bar). The rela-
tive protein expression is reported as average ± standard deviation of 
three independent protein preparations and quantifications per sample 
*p < 0.05, **p < 0.005
911Acta Neuropathologica (2019) 137:901–918 
1 3
DPP6 coding exons and searched for rare, protein chang-
ing variants in 558 EOAD (mean onset age 61.6 ± 6.8 years, 
range 33–70) and 614 (mean onset age 66.1 ± 9.9 years, 
age range 20–89) FTD patients. We identified two prema-
ture termination codon (PTC) mutations, p.E79Gfs*9 and 
p.Q23O* in two FTD patients, which were absent from 
755 matched controls (mean inclusion age 71.6 ± 9.7 years, 
age range 34–100) (Table 1 and Table S2). In addition, we 
identified 22 missense variants and a size variable in-frame 
Gly-insertion/deletion in exon 1 in AD, FTD patients and 
controls (Table 1, Table S2 and Table S3). We obtained a 
significant association (SKAT-O) of rare variants in DPP6 
(minor-allele frequency (MAF) < 0.01) in both AD (n = 558, 
p = 0.03, OR = 2.21 95% CI 1.05–4.82) and FTD (n = 614, 
p = 0.006, OR = 2.59, 95% CI 1.28–5.49) cohorts.
Rare variants alter DPP6 and  Kv4.2 expression levels 
in brain tissue of patients
Frozen autopsy brain was only available of three patients 
carrying a DPP6 missense variant. These patients had a 
probable clinical diagnosis of primary progressive apha-
sia (PPA, logopenic variant), FTD (behavior variant) plus 
Paget’s disease of the bone, and FTD plus ALS (bulbar 
type) (Table S4).The neuropathological diagnoses were AD 
(DR414), FTLD-TDP type D (DR40) and FTLD-ALS type B 
(DR1152) (Fig. S3). Patient DR40 also carried a causal VCP 
mutation, p.R159H (Table S4). For all three DPP6 variants 
p.P509R, p.R47L, and p.D596N, we observed significantly 
reduced mRNA levels (p = 0.0096, Fig. 4a, b), and a marked 
decrease in DPP6 protein expression levels in the p.P509R 
and p.R47L carriers (p = 0.03) (Fig. 4c, d). Moreover, the 
protein levels of the potassium channel  Kv4.2, binding part-
ner of DPP6, were also severely reduced (Fig. 4e, f).
Rare variants in the extracellular domain of DPP6 
destabilize the protein and alter its membrane 
expression
In silico modeling of the missense variants located in the 
extracellular domain of DPP6, predicted a destabilizing 
effect, measured in positive values of free Gibbs energy, for 
7/10 (70%) of the missense variants found in patients only 
(Table 1, Table S3, Fig. 5). The three variants (p.V220I, 
p.G269R and K570N), found in controls only, were all pre-
dicted to stabilize the protein (ΔΔG < −1). A similar sta-
bilizing effect was detected for the variant p.A778T found 
in both patients and controls. Furthermore, investigation 
of the intramolecular interaction with functional residues 
showed that two missense variants (p.R322H and p.D569N), 
detected only in patients, could have a deleterious effect 
on protein glycosylation, either because of the conforma-
tional location nearby the canonical glycosylated residue, as 
p.R322H is in the vicinity of the glycosylation site N319, or 
because of the amino acid change itself (p.D569N), which 
could compete for the glycosylation with the closely local-
ized glycosylation site N566 (Fig. S5). Similar to p.R322H, 
the variant p.K571Q, present only in patients, could compro-
mise the glycosylation of residue N173 (Fig. S6).
Since DPP6 is known to localize on the plasma mem-
brane, we monitored DPP6 stability as changes in DPP6 
abundance on the plasma membrane due to folding proper-
ties or stability issues or retention in one of the organelles 
(e.g., endoplasmic reticulum) in the presence of missense 
variants. To this end, we generated C-terminally Nano-Glo® 
HiBiT tagged DPP6 constructs and compared wild-type 
against its missense variants in HEK293T cells. The wild-
type construct fused with the PEST sequence, promoting an 
accelerated degradation, was used as an internal control and 
the p.Q230* construct was used as a negative control. Of the 
14 modeled missense variants located in the extracellular 
domain of DPP6 (Table 1, Table S2, Fig. 5a), we observed 
a significant reduced expression (p value < 0.001, Fig. 5) on 
the plasma membrane for 5/10 (50%) of the variants found 
in patients only (Table 1, Fig. 5). Their CADD scores range 
from 15.06 for p.E208Q to 34 for p.R247H. The latter vari-
ant showed the most drastic reduction of the plasma mem-
brane expression of DPP6 next to the p.Q230*, which was 
not expressed at all. A significant reduction was observed 
for one variant (p.G269R) found in controls only. No signifi-
cant differences were recorded for the variants starting from 
amino acid position 570. Western blot analysis of the overall 
DPP6 protein expression showed that the detected differ-
ences in DPP6 plasma membrane expression levels were 
not due to direct changes in total protein abundance (Fig. 
S7). Moreover, immunofluorescence staining showed proper 
protein localization on the plasma membrane (Fig. S8).
Discussion
The 4 Mb inversion at 7q36 is disrupting DPP6 
causing dementia in family 1270
Our family-based genetic and genomic investigation evi-
denced the presence of a 4 Mb paracentric inversion at 
7q36, segregating on the disease haplotype and explain-
ing the linkage in family 1270. This chromosomal rear-
rangement was detected by two independent sequencing 
technologies. Furthermore, the direct long-read sequenc-
ing on PromethION, mapped the two breakpoints on 
chr7:149,704,610–153,786,893. The inversion is likely 
triggered by the presence of inverted paralogous LCRs 
(IP-LCRs) with high (> 98%) homology and located 4 Mb 
apart. This notion is supported both by our DNA local 
alignments and the data of a genome-wide IP-LCRs search, 
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demonstrating that the DPP6 locus is enriched for IP-LCRs 
[17]. IP-LCRs can cause genomic instability by non-allelic 
homologous recombination (NAHR) mediated by the inver-
sion [17, 22] and this can be associated with disease traits 
[17, 21]. The family 1270 inversion breakpoint in DPP6, is 
predicted to prevent the transcription of the mutant allele 
leading to loss of DPP6, suggesting that the underlying dis-
ease mechanism in family 1270 is haploinsufficiency. The 
absence in the short- and long-read WGS datasets of the 
inversion observed in family 1270, is an indication that this 
inversion is most likely a rare event. The genomic region 
at 7q36 is known to be vulnerable for structural alterations 
and chromosomal rearrangements such as copy number 
variations and translocations [42, 43, 47, 48, 63]. Different 
breakpoints have been associated with other disease pheno-
types including neurodevelopmental disorders [43, 47, 63]. 
Each of these genomic rearrangements was affecting a single 
family or a few patients. Larger datasets of long-read WGS 
and new bioinformatics tools are needed to obtain a more 
accurate measure of the frequency of structural variants in 
the 7q36 region [13, 14].
Genetic association of DPP6 in dementia
To better understand the genetic contribution of DPP6 to 
NBD and to support haploinsufficiency as the mode of 
action, we re-sequenced the coding region of DPP6 and 
identified nonsense and frameshift variants, and several mis-
sense and short indels that were scattered over the whole 
DPP6 gene in patients. The p.Q230* and p.E79Gfs*9 vari-
ants, were found in a FTD and FTD-ALS patient who were 
67 and 76 years at inclusion in the FTD cohort. These PTC 
variants likely lead to DPP6 haploinsufficiency through non-
sense-mediated decay (NMD) of their mutated transcript. 
While we did not have brain tissue of the two PTC carriers, 
an independent study confirmed NMD of a DPP6 PTC vari-
ant with 41% reduction of DPP6 transcript levels in the cor-
tex of a definite FTLD patient supporting the loss of DPP6 
as the underlying biological mechanism [62].
Since we lacked biosamples to confirm transcript deg-
radation under physiological conditions, mutation mode-
ling of the p.Q230* PTC variant located in the extracellu-
lar domain of DPP6, supported the loss of DPP6 protein. 
In controls, the missense and indel variants were mainly 
clustering in the non-conserved intracellular protein 
domain (exon 1) while PTC variants were not observed. 
The carriers of DPP6 variants observed only in patients, 
had an average onset age of 62.9 (n = 12, range 44–77) 
and an inclusion age of 66.1 (n = 22, range 50–81) years, 
which is comparable to the ages and age range observed 
in family 1270, which is 66.8 ± 7.4 years (n = 13; range 
47–77). Highly variable onset ages have been reported 
in patients and families with mutations leading to loss-
of-protein, i.e., in GRN [10] in FTD and in ATP-binding 
cassette subfamily a member 7 gene (ABCA7) [74] in 
AD. These genes also show a wide spectrum of muta-
tions having different effects on expression and found 
over a larger onset age range from early- to late-onset [8, 
74]. The GRN and ABCA7 findings indicate that these 
mutations have different risk contributions to disease 
that can vary from high to low penetrance [56, 79] which 
could be valid also for DPP6 missense variants. Since 
the extracellular domain of DPP6 is highly structured, 
missense variants in this domain could affect the protein 
conformation, its function or the interaction with addi-
tional proteins. Additional studies are needed to further 
understand how these variants act. In our study, we did 
not identify a correlation between DPP6 rare variants and 
a specific phenotypic trait including age at onset, disease 
duration and family history. However, taken the small 
number of patients in our cohort and the rarity of DPP6 
variants, the analysis was likely underpowered and addi-
tional studies will be needed. Furthermore, the SKAT-O 
analysis showed an enrichment of DPP6 rare variants in 
both AD and FTD patients, with a stronger significance 
level in FTD (p = 0.006), in which we also identified 
the PTC variant carriers (0.3%, 2/614). This is in line 
with an independent genome-wide association study on 
whole genome sequencing on FTD with TDP-43 (TAR 
Fig. 5  In silico and in  vitro modeling of rare variants (MAF < 1%) 
identified in the screened cohorts. a On scale representation of rare 
variants (MAF < 1%) detected by DPP6 resequencing. The structural 
domains [72] are IC, intracellular domain (blue), TM, transmem-
brane domain (dark green) and EC, extracellular domain including 
the α/β hydrolase (pink) and the β-propeller domains (turquoise). 
Seven predicted glycosylation sites are reported as black balls on 
sticks. DPP6 is a type II transmembrane protein, the N-terminal 
 (NH3+) and the C-terminal  (COO−) are marked. Variants located in 
the transmembrane domain (dark green) and extracellular domain are 
common to all DPP6 isoforms here are represented on the canonical 
isoform (NM_130797.2). Variants in the intracellular domain (exon 
1) are isoform specific. Apart from variants in the variable intracel-
lular domain in the canonical isoform NM_130797.2 (isoform 1), 
we detected one additional variant (p.A5D) in exon 1 of isoform 3 
(NM_001039350.2) not represented in the figure. Represented in 
red are variants identified in patients only, in green are depicted the 
variants identified in control individuals only and in black in both 
patients and control individuals. Variants marked with a black arrow 
were included in expression studies, since brain tissue of the carri-
ers was available. b Prediction of protein stability in the presence of 
the missense variants measured in differences in free Gibbs energy 
(ΔΔG). Destabilizing or stabilizing variants result in positive or 
negative values, respectively. c In  vitro protein stability assay using 
HiBiT-tagged constructs carrying the variants of interest compared 
to wild-type DPP6. DPP6 fused to the PEST sequence (WT-PEST) 
was used as positive control. Graph bars represent normalized lumi-
nescence (RLUC) that were used to compare the mutated constructs 
with the wild-type DPP6. Reported data are the pooled results of six 
independent experiments, error bars represent standard deviation. 
***p < 0.001; ****p < 0.0001
◂
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DNA binding protein 43) pathology [62]. Two common 
SNPs in intron 1 of DPP6 showed genome-wide signifi-
cant association (rs4726389 p = 4.63e−8, OR = 2.45 and 
rs118113626 p = 4.88e−08, OR = 2.48) [62]. Moreover, 
one PTC carrier was identified amongst the FTLD-TDP43 
patients and never in controls, thus matching our findings 
[62].
Functional and expression analyses support DPP6 
loss as disease mechanism
Understanding the effect of missense variants, compared 
to PTC mutations, is not trivial. We used the Nano-Glo® 
HiBiT assay to further characterize the missense variants 
we identified in DPP6. We monitored the changes in DPP6 
abundance on the plasma membrane, as in silico analysis 
predicted differences in protein stability due to alterations 
in folding properties in 7/10 variants found in patients only 
in the extracellular domain. The in vitro modeling showed 
that five variants (p.E208Q, p.R274H, p.R322H, p.H357R 
and p.509R) identified in patients only, destabilize the pro-
tein leading to a reduced level on the plasma membrane, 
suggesting a loss of function. This was also detected in one 
variant (p.G269R) found in a control person, suggesting that 
the missense variants might have a different risk contribution 
and that the mode of action of missense variants can involve 
different mechanisms, e.g., the protein function, interaction 
with other proteins not investigated by this assay. The pre-
dictions and the in vitro experiment did not completely over-
lap, stressing the need for in vitro validation in support of in 
silico prediction analyses. The in vitro assay correlates with 
the DPP6 protein levels measured in brain of two carriers 
of a missense variant. In fact, DR414, carrier of p.P509R, 
showed reduced DPP6 brain protein expression, in accord-
ance to the protein destabilization detected in vitro. While 
in the brain tissue of DR1152, carrier of the p.D569N, there 
were no evident reductions, in agreement with the in vitro 
assay, suggesting a possible alternative mode of action of 
this specific variant, for example protein glycosylation. This 
is supported by the alterations detected in brain expression 
levels of the  Kv4.2 for this variant carrier. The fact that 50% 
of the patient-specific variants that we modeled in vitro, 
have a deleterious effect is a relevant consideration to make, 
because of the highly structured extracellular domain of 
DPP6 [72], which is crucial for the protein expression and 
function, with the different protein domains of DPP6 respon-
sible for its protein localization [44]. In light of this, we sug-
gest a loss of function effect also for these missense variants 
located in the extracellular domain.
In terms of protein function, DPP6 belongs to the dipep-
tidyl-peptidase protein family, but lacks protease activity 
because of a serine into aspartic acid change in the catalytic 
peptidase domain [72]. By binding, most likely, at the per-
meation and gating modules [35] of the potassium channel 
 Kv4.2, DPP6 enhances its expression and regulates its gat-
ing properties [35, 51, 52, 73] and it is known to control the 
dendritic excitability of the hippocampal neurons [73] and 
the neuronal plasticity [36]. DPP6 and  Kv4.2 directly interact 
in a multimeric protein complex, in which  Kv4.2 is addition-
ally bound to the auxiliary potassium channel interacting 
proteins (KChIP) [33]. Reduced potassium and persistent 
enhanced sodium currents converge to produce neuronal 
hyperexcitability [81]. A recent study on Dpp6 knockout 
(KO) mice suggested a structural function in the formation 
of filopodia, the precursor of the dendritic spines, and in cel-
lular stability through the binding to the extracellular matrix, 
thus directly affecting dendritic arborization, spine density 
and synaptic function [46]. Furthermore, DPP6 loss has been 
shown to determine memory and learning impairments in 
young Dpp6-KO mice [45]. Patients affected by anti-DPPX 
syndrome, with autoantibodies targeting DPP6 and caus-
ing reduced protein expression, have memory deficits and 
neuronal hyperexcitability, features that are improved when 
DPP6 expression levels are increased [27]. Taken together 
our data and these studies point toward a deleterious effect 
of DPP6 loss and support its contribution to dementia.
Conclusions
Our investigations show that the loss of DPP6 can occur 
on different levels: the genomic level, with the inversion 
disrupting the coding sequence; the genetic level with the 
identification of PTC and deleterious missense variants as 
well as the protein level, where different variants show a 
spectrum of alteration in the cellular surface expression. The 
genetic association with rare variants is an additional line 
of genetic evidence to link DPP6 to dementia. Our assays 
to model the missense variants suggest that not all variants 
identified are deleterious, like the variants located in the ɑ/β 
hydrolase domain (e.g., p.A778T), This is not unexpected, 
knowing that widely accepted causal genes for dementia are 
known to harbor benign variants [9].
The involvement of DPP6 in diverse and independent cel-
lular pathways including neurogenesis and neuronal excit-
ability, could explain why loss of DPP6 was associated with 
autosomal dominant microcephaly with mental retardation 
[43] and other neurodevelopmental disorders, including 
Gilles de la Tourette syndrome (TS) [63] and autism spec-
trum disorders (ASD) [47]. Heterozygous loss of DPP6 may 
not represent a single cause of severe intellectual disabil-
ity but it is likely a susceptibility factor to this phenotype 
[63]. Currently the link between neurodevelopment and 
915Acta Neuropathologica (2019) 137:901–918 
1 3
neurodegeneration is unclear, but parallels between the two 
mechanisms have been proposed [82].
Alterations in the homeostasis of neuronal firing [24] and 
early neuronal network dysfunctions [58, 84] are emerging 
concepts in neurodegenerative brain diseases. The results 
of our genomic, genetic, expression and modeling analyses, 
provide direct evidence to support the involvement of DPP6 
loss in dementia, with loss of function variants (PTC, inver-
sion) having a higher penetrance and disease impact and 
missense variants having a variable risk contributions to dis-
ease from high to low penetrance [56, 79]. Additional stud-
ies are needed to fully understand the role of these variants 
in the disease etiology. Our findings on DPP6, as a novel 
genetic factor in dementia, provide supportive evidence to 
the emerging concept that neuronal hyperexcitability and 
alteration of the homeostasis of neuronal firing represent a 
relevant disease mechanism warranting further investigation.
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